Royalty Pharma Plc Market Cap ($29.25 Billion)
Market Cap & Net Worth: Royalty Pharma Plc (RPRX)
Royalty Pharma Plc market cap. Royalty Pharma Plc (NASDAQ:RPRX) has a market capitalization of $29.25 Billion ($29.25 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #898 globally and #396 in its home market, demonstrating a 5.38% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Royalty Pharma Plc's stock price $67.18 by its total outstanding shares 443274104 (443.27 Million).
Royalty Pharma Plc Market Cap History (2020–2026)
Royalty Pharma Plc market cap history from 2020 to 2026. Data shows growth from $20.27 Billion to $29.78 Billion (8.33% CAGR). Check RPRX share price today for real-time trading data and today's change.
Index Memberships
Royalty Pharma Plc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
ARCA Pharmaceutical
DRG
|
$3.45 Trillion | 0.85% | #12 of 24 |
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 1.12% | #14 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.07% | #116 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 1.59% | #10 of 263 |
Weight: Royalty Pharma Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Royalty Pharma Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Royalty Pharma Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see RPRX cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
7.20x
Royalty Pharma Plc's market cap is 7.20 times its annual revenue
Latest Price to Earnings (P/E) Ratio
22.22x
Royalty Pharma Plc's market cap is 22.22 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $20.27 Billion | $2.12 Billion | $975.04 Million | 9.55x | 20.79x |
| 2021 | $16.40 Billion | $2.29 Billion | $619.73 Million | 7.16x | 26.46x |
| 2022 | $16.56 Billion | $2.24 Billion | $42.83 Million | 7.40x | 386.66x |
| 2023 | $12.08 Billion | $2.35 Billion | $1.13 Billion | 5.13x | 10.64x |
| 2024 | $11.31 Billion | $2.26 Billion | $858.98 Million | 5.00x | 13.16x |
| 2025 | $17.13 Billion | $2.38 Billion | $770.95 Million | 7.20x | 22.22x |
Competitor Companies of RPRX by Market Capitalization
Companies near Royalty Pharma Plc in the global market cap rankings as of October 31, 2026. See how leveraged is Royalty Pharma Plc's balance sheet to understand what proportion of total assets are financed by equity.
Key companies related to Royalty Pharma Plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Royalty Pharma Plc (2020–2026)
Market capitalization of Royalty Pharma Plc from 2020 to today. Between 2020 and today, Royalty Pharma Plc's market cap moved from $20.27 Billion to $ 29.78 Billion, with a yearly change of 8.33%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $29.78 Billion | +73.86% |
| 2025 | $17.13 Billion | +51.47% |
| 2024 | $11.31 Billion | -6.36% |
| 2023 | $12.08 Billion | -27.08% |
| 2022 | $16.56 Billion | +0.99% |
| 2021 | $16.40 Billion | -19.09% |
| 2020 | $20.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Royalty Pharma Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.25 Billion USD |
| MoneyControl | $29.25 Billion USD |
| MarketWatch | $29.25 Billion USD |
| marketcap.company | $29.25 Billion USD |
| Reuters | $29.25 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Royalty Pharma Plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabe… Read more